MONTREAL — Scientists at the Montreal Clinical Research Institute (IRCM) have identified a previously unknown immune-suppressing mechanism that may explain why some cancer therapies lose effectiveness over time. The findings, published in the journal Nature, focus on a molecule called SLAMF6 located on the surface of immune cells.
Dr. André Veillette, a medical professor at the Université de Montréal and leader of the research team, explained that SLAMF6 can prevent T cells from launching a robust attack against tumors. Unlike many other immune-suppressing molecules, SLAMF6 has the unique ability to activate itself directly on the surface of T cells. This self-activation triggers signals that weaken the body’s natural defenses against cancer, a process previously unknown to scientists.
The discovery carries significant implications for cancer immunotherapy, a treatment approach that includes drugs such as PD1 and PDL1 inhibitors. These therapies work by removing inhibitory signals that tumors create to evade the immune system.
However, a considerable number of patients either do not respond to these treatments initially or eventually develop resistance. The IRCM team found that SLAMF6 can act as a major obstacle to treatment success. Even when other inhibitory signals are removed by existing immunotherapies, SLAMF6 can continue to suppress the immune response, allowing tumors to persist.
In a potential breakthrough, the researchers have developed monoclonal antibodies designed to block SLAMF6 from binding to itself and triggering its suppressive signals. Laboratory tests have shown promising results for these newly created antibodies.
The research team believes this approach could form the basis of a new treatment option for cancer patients, particularly those who have not benefited from current therapies. Understanding how cancers evade the immune system is central to developing more effective treatments. By studying molecules like SLAMF6 and others that suppress immune responses, scientists aim to find ways to boost the body’s natural defenses against cancer.
The development of antibodies that can block SLAMF6 represents a significant step forward in cancer research. The team plans to continue investigating this molecule and its role in immunotherapy.
As the field evolves, discoveries such as this one offer hope for more effective treatments and improved outcomes for patients. Individuals seeking medical advice should consult their healthcare provider.
